NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.25 -0.02 (-0.38 %)
(As of 07/18/2018 02:52 AM ET)
Previous Close$5.28
Today's Range$5.20 - $5.30
52-Week Range$4.85 - $9.95
Volume152,800 shs
Average Volume706,590 shs
Market Capitalization$322.85 million
P/E Ratio-8.08
Dividend YieldN/A
Corbus Pharmaceuticals logoCorbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. The company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. Corbus Pharmaceuticals Holdings, Inc. was founded in 2009 and is based in Norwood, Massachusetts.

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio7.25
Quick Ratio7.25


Trailing P/E Ratio-8.08
Forward P/E Ratio-6.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.44 million
Price / Sales122.94
Cash FlowN/A
Price / CashN/A
Book Value$1.04 per share
Price / Book5.05


EPS (Most Recent Fiscal Year)($0.65)
Net Income$-32,420,000.00
Net MarginsN/A
Return on Equity-76.01%
Return on Assets-64.57%


Outstanding Shares57,140,000
Market Cap$322.85

The Truth About Cryptocurrencies

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.11. The biopharmaceutical company earned $0.95 million during the quarter, compared to the consensus estimate of $6.25 million. View Corbus Pharmaceuticals' Earnings History.

What price target have analysts set for CRBP?

3 brokers have issued twelve-month target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $20.00 to $32.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $25.3333 in the next twelve months. This suggests a possible upside of 382.5% from the stock's current price. View Analyst Ratings for Corbus Pharmaceuticals.

What is the consensus analysts' recommendation for Corbus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Corbus Pharmaceuticals' key competitors?

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the folowing people:
  • Dr. Yuval Cohen, CEO & Director (Age 43)
  • Dr. Mark A. Tepper Ph.D., Co-Founder, Pres & Chief Scientific Officer (Age 61)
  • Dr. Barbara White M.D., Chief Medical Officer (Age 68)
  • Mr. Sean F. Moran CPA, MBA, CFO & Principal Accounting Officer (Age 60)
  • Scott Constantine M.S., Director of Clinical Research & Operations

Has Corbus Pharmaceuticals been receiving favorable news coverage?

Media headlines about CRBP stock have been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corbus Pharmaceuticals earned a daily sentiment score of 0.06 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.05%). Company insiders that own Corbus Pharmaceuticals stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

Which institutional investors are buying Corbus Pharmaceuticals stock?

CRBP stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $5.25.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $322.85 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]

MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.